Novartis today convened leading experts from science, policy, patient advocacy, and clinical care to spotlight elevated lipoprotein(a), or Lp(a) – a little-known but highly prevalent genetic risk factor for cardiovascular disease (CVD) that affect 1 in 5 people worldwide.1 The global
